Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine [lamivudine/abacavir] (3TC) [Epzicom] to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) [emtricitabine/tenofovir disoproxil fumarate] [Truvada] in Virologically Suppressed, HIV 1 Infected Patients Maintained on a Ritonavir Boosted Protease Inhibitor Containing Antiretroviral Regimen.

Trial Profile

A Prospective, Randomized, Open Label Phase IV Study to Evaluate the Rationale of Switching From Fixed Dose Abacavir (ABC)/Lamivudine [lamivudine/abacavir] (3TC) [Epzicom] to Fixed Dose Tenofovir DF (TDF)/Emtricitabine (FTC) [emtricitabine/tenofovir disoproxil fumarate] [Truvada] in Virologically Suppressed, HIV 1 Infected Patients Maintained on a Ritonavir Boosted Protease Inhibitor Containing Antiretroviral Regimen.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; HIV protease inhibitors; Lamivudine/abacavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms SWIFT
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 23 Oct 2011 Results presented at the 49th Annual Meeting of the Infectious Diseases Society of America.
    • 12 Oct 2011 Results presented at the 13th European AIDS Conference.
    • 20 Sep 2011 Results presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top